You searched for "DMO"
Steroid treatment for pseudophakic cystoid macular oedema
The authors present a retrospective comparison of 45 eyes of 41 patients treated with 2mg intravitreal triamcinolone (IVT group) and 50 eyes of 42 patients treated with 40mg sub-Tenons triamcinolone (STT group) for pseudophakic cystoid macular oedema (CMO). The visual...
Steroid implants in the treatment of post-epiretinal membrane peel macular oedema
This is a retrospective review of 39 eyes of 37 patients treated with Ozurdex® (intravitreal dexamethasone implant) for persistent post-operative cystoid macular oedema (CMO) following vitrectomy and idiopathic epiretinal membrane (ERM) peeling. The 0.7mg implant was injected in each eye...
VIBIM Study: One-year results of treatment of DME with aflibercept using TnE
The VIBIM study (the treat-and-extend regimen (TER) using intravitreal aflibercept in diabetic macular edema (DME) study) was designed to evaluate the efficacy of the TER using aflibercept in the management of DME for a period of two years. The authors...
OCTA in diabetic macular oedema treated with intravitreal aflibercept (DOCTA Study)
Central vision loss due to diabetic macular oedema (DME) can be attributed not only to presence of the macular oedema itself but also, in some cases, to alterations of the foveal avascular zone (FAZ). The DOCTA trial was a longitudinal,...Telemedicine strategies in ophthalmology: harnessing established and emerging technologies for lasting solutions
The author considers recent progress and shares insights from leading practitioners in telemedicine applications and digital technology strategies. Amidst COVID-19 and combined mitigation and suppression measures, hospitals and clinics have responded rapidly to strengthen telemedicine strategies and virtual healthcare services...
Systemic pharmacology of intravitreal anti-VEGF
This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...
Topical nonsteroidal ant-inflammatory drugs (NSAIDs) in patients undergoing cataract surgery
Inflammation is a major risk factor for the development of cystoid macular oedema (CMO) after cataract surgery, leading to breakdown of the blood-retina barrier. There is a correlation between severity of CMO and level of postoperative inflammation. Laser flare meter...
Evaluation of fluocinolone acetonide in the management of BRC
This is a single-centre, retrospective, intervention study of 15 eyes of birdshot retinochoroiditis (BRC) patients who received Iluvein, with a mean follow-up period of 31 months. Five eyes had previously received dexamethasone intravitreal implant 0.7mg (Ozurdex). Fluorescein angiography (FA) showed...
Diclofenac versus Bromfenac after cataract surgery
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used after cataract surgery to reduce inflammation and cystoid macular oedema (CMO). Diclofenac 0.1% is used three to five times daily for 28 days and Bromfenac 0.09% twice daily for 14 days postoperatively. The...
Smoking and Behçet’s disease
This study aimed to investigate the relationship between smoking and prognosis of ocular Behçet’s disease (BD). Records of 202 patients with ocular features of BD were reviewed from a Turkish hospital. Patients were divided into two groups according to their...
25-gauge PPV for retained lens fragments
This was a retrospective study including 40 eyes of 40 patients with mean age of 78 years, 19 females and 21 males, who underwent 25-gauge pars plana vitrectomy (PPV) for retained lens fragments with a minimum of six months of...
